Finance

A look at the driving factors behind renewed optimism.

A recent analysis of the biotech market shows promising signs.

Kobel discusses taking a company public during a challenging time in the market.

COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.

A summary of key takeaways from EY’s new Beyond Borders report.

Restructuring and ensuring the right talent is in place can help life sciences industry push through latest downward spiral.

Some observations point to hope for an upturn.

Living to fight another day, as potential investment spark looms.

What will current stranglehold mean for industry down the line?

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

Full-year business review of pharma and biotech sectors reveals strong momentum in advancing novel science and treatments, but likely foretells continued stock instability in near-to-medium terms.

But a doubling-down on R&D offers reason for optimism.

Biopharma stock performance continues to struggle.

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Ahead of the release of EY’s annual M&A Firepower report this week, Pharm Exec talks to EY’s Arda Ural to review biopharma M&A activity in 2021 and to discuss the likely deal drivers of 2022.

Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.

Industry growth in innovation could spark financial rebound.

Regulatory headwinds are poised to ease as new year approaches.

While Q3 numbers look bleak, is improvement on the horizon?

Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.

With large M&A deals comes a complex Market Authorization Transfer (MAT) process, during which regulatory teams must weigh several operational aspects while creating a roadmap that takes them into account. Cecile Riboud outlines some key questions that are necessary for planning and executing a successful MAT process.

But could there be a shift in momentum?

Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.

A remarkable run indeed, but cost questions can’t be ignored.

What are the reasons behind the slump and what does the future hold?